April 19, 2021
1 min read

FDA grants priority review to Padcev for advanced urothelial cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to two supplemental biologics license applications for enfortumab vedotin-ejfv in the treatment of locally advanced or metastatic urothelial cancer.

The first application seeks to convert the accelerated approval of enfortumab vedotin-ejfv (Padcev; Astellas, Seagen) to regular approval, based on results of the phase 3 EV-301 trial. As Healio previously reported, results of that trial showed enfortumab vedotin-ejfv conferred significantly longer median OS (12.88 months vs. 8.97 months; HR = 0.7; 95% CI, 0.56-0.89) and PFS (5.55 months vs. 3.71 months; HR = 0.62; 95% CI, 0.51-0.75) compared with investigator-chosen chemotherapy among 608 patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-containing chemotherapy and had progressed during or after treatment with a PD-1 or PD-L1 inhibitor.

FDA sign
Source: Adobe Stock.

The second application seeks to expand approval of enfortumab vedotin-ejfv to include patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin and who previously received a PD-1 or PD-L1 inhibitor. That application is based on data from the EV-201 trial, which showed a confirmed overall response rate of 52% (95% CI, 40.8-62.4) in a cisplatin-ineligible population.

The applications will be revied under Project Orbis, an initiative of the FDA Oncology Center of Excellence, with a target action date of Aug. 17.